Personal Data

Cedric RAOULName: Cédric RAOUL
Business Address:
The Neuroscience Institute of Montpellier, Inserm UMR1051, 80 rue Augustin Fliche, 34095 Montpellier, France Laboratory of Neurobiology, Kazan Federal University, 420008, Kazan Federal (Volga Region) University, Karla Marska 76, Kazan, Russia

Phone: +33 4 99 63 61 15; +7 (843) 233 78 24
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
Date of Birth: 08.02.1973


Education and Academic Degrees

  • 2008 Research supervisor qualification (habilitation) in Neuroscience, Aix-Marseille University, Marseille, France
  • 2002 Ph.D (Cell Biology), Inserm U382, Developmental Biology Institute of Marseille, Marseille, France


Positions held

  • 2012 - Inserm Research Director, DR2
  • 2012 - Team leader, Inserm, INM, Montpellier, France
  • 2006-2011 - Team leader, Inserm-Avenir, Inserm U901, INMED, Marseille, France
  • 2006 - Inserm research associate, CR1 (ranked first)
  • 2002-2006 - Post-doctoral fellow, Brain Mind Institute, EPFL, Lausanne, Switzerland


Areas of Specializations

Amyotrophic lateral sclerosis (ALS) is a relentlessly fatal neurodegenerative disorder that primarily affects motoneurons in the brain and spinal cord. While the neurodegenerative process selectively affects motoneurons, the underlying factors also involve non-cell-autonomous determinants. Indeed, glial cells, including astrocytes, microglial cells, oligodendrocytes and immune cells contribute to the pathogenic process.

Our mission is to 1) understand how the cellular environment contributes to the degeneration of motoneurons in amyotrophic lateral sclerosis (ALS) and other motoneuron disorders, 2) develop new therapeutic strategies. Our research is carried out by a multidisciplinary team of neurobiologists, electrophysiologists, immunologists, clinicians, and geneticists.

Keywords: Motoneuron, Neuroinflammation, Neuroimmunity, synaptic transmission, Neuromuscular junction, Gene Therapy, Human Molecular Genetic, mouse, drosophila.



  • Since 2007: 22 financial contracts from USA, European or French programs : ANR, ERA-NET E-RARE, American ALS association, Target ALS foundation, Marie Sklodowska-Curie


Editorial tasks and Peer reviewing

  • Academic editor of PLoS One and the Journal of Neurodegenerative Diseases
  • Review Editor at Frontiers in Cellular Neuroscience
  • Member of the scientific council of the French Association against Myopathy (AFM), “gene and/or cell therapy of rare disorders”. (2010-)
  • Vice-president of the scientific council of the French association for the research against ALS (ARSLA)(2016-2022)
  • Member of the scientific council of the ARSLA (2010-present)
  • Member of the European Science Foundation (ESF) reviewer panel (2017-2019)
  • Member of the ESF college of expert reviewers (2019-2022)
  • Member of the reviewer panel of AFM strategic program (2018)
  • Member of the Caixa Foundation reviewer panel (2018-)
  • Member of the scientific advisory board of LASCCO SA, Geneva, Switzerland
  • Member of the scientific advisory board of SIGMATHERA SA, Montferrier, France
  • Member of 15 Ph.D Jury and 5 HDR committees
  • Solicited reviewer for 31 peer-reviewed journals
  • Solicited reviewer of 17 funding organization



  • 2018 - Prize Fabrice Le Mouhaer on ALS research, Foundation for Medical Research (FRM)
  • 2010 - Inserm scientific excellence award
  • 2006 - Inserm-Avenir program laureate
  • 2005 - Travel grant award, American Society of Gene Therapy



Spinal Motoneuron TMEM16F Acts at C-boutons to Modulate Motor Resistance and Contributes to ALS Pathogenesis.

Soulard, C., Salsac, C., Mouzat, K., Hilaire, C., Roussel, J., Mezghrani, A., Lumbroso, S., Raoul, C*., and Scamps, F*. (2020). Cell Rep 30, 2581-2593 e2587. *equal contribution/co-corresponding authors.